Seth Klarman
Baupost Group
Seth Klarman Cascadian Therapeutics Inc stake
total: 272
Baupost Group CASC trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2016 Q2
- Held for:
- 7 quarters
- Latest activity:
- 2018 Q1
According to 2026 Q2 report, Seth Klarman doesn't hold any Cascadian Therapeutics Inc (CASC) shares. To date, the estimated cost basis is nearly $1.44 for "buy" trades and estimated average "sell" price is $4.13. Baupost Group first purchased CASC in 2016 Q2, initially acquiring about 25.00M shares. Since the initial investment in Cascadian Therapeutics Inc (CASC), Baupost Group has made 3 more transactions.
When did Seth Klarman sell Cascadian Therapeutics Inc (CASC)?
Seth Klarman sold off the entire Cascadian Therapeutics Inc (CASC) position in 2018 Q1.
When did Seth Klarman buy Cascadian Therapeutics Inc (CASC)?
Seth Klarman first invested in Cascadian Therapeutics Inc (CASC) in 2016 Q2 at the reported quarter-end price of $0.94 per share.
What's the cost basis of Baupost Group's CASC stake?
The estimated cost basis for Cascadian Therapeutics Inc (CASC) stake is around $1.44 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $1.44
- Weighted AVG sell price:
- $4.13
Seth Klarman's historical trades in Cascadian Therapeutics Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q1
|
0.00%
|
$3.70
|
-100% (-8,721,079)
|
|||
|
2017 Q1
|
0.43%
|
$4.14
|
+109.31% (+4,554,413)
|
|||
|
2016 Q4
|
0.23%
|
$4.31
|
-83.33% (-20,833,334)
|
|||
|
2016 Q2
|
0.32%
|
$0.94
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.